JP Patent

JP7242222B2 — ロフルミラストの結晶成長の妨害

Assigned to アーキュティス・バイオセラピューティクス・インコーポレーテッド · Expires 2023-03-20 · 3y expired

What this patent protects

Patent listed against Daliresp.

Drugs covered by this patent

Patent Metadata

Patent number
JP7242222B2
Jurisdiction
JP
Classification
—
Expires
2023-03-20
Drug substance claim
No
Drug product claim
No
Assignee
アーキュティス・バイオセラピューティクス・インコーポレーテッド
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.